Entry Detail



General Information

Database ID:exR0087907
RNA Name:hsa-miR-20a-5p
RNA Type:miRNA
Chromosome:chr13
Starnd:+
Coordinate:
Start Site(bp):91351072End Site(bp):91351094
External Links:hsa-miR-20a-5p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE101841
Description:Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:Trastuzumab therapy
Case Disease Type:Breast Cancer
Case Disease SubType:HER2 positive metastatic breast cancer
Case Sample:Breast Cancer Trastuzumab resistant
Control Sample:Trastuzumab sensitive
Number of Case:42
Number of Control:61
Number of Samples:103





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
RIPOR1
chr16
67518418
67546788
+
EIF5A2
chr3
170888418
170908644
-
RCCD1
chr15
90954870
90963125
+
FHL1
chrX
136146702
136211359
+
ZFAND4
chr10
45615500
45672780
-
CLOCK
chr4
55427903
55546909
-
NSD1
chr5
177133025
177300215
+
ZDHHC12
chr9
128720870
128724127
-
PXYLP1
chr3
141228726
141367753
+
C9orf40
chr9
74946583
74952912
-
PBXIP1
chr1
154944076
154956123
-
ZNF468
chr19
52838010
52857649
-
ATXN1
chr6
16299112
16761491
-
SCAMP2
chr15
74843730
74873365
-
SLC46A3
chr13
28700064
28718970
-
GNAS
chr20
58839718
58911192
+
MBP
chr18
76978827
77133683
-
AMPD2
chr1
109616104
109632053
+
PXDN
chr2
1631887
1744852
-
WDR37
chr10
1049538
1132384
+
CYLD
chr16
50742050
50801935
+
ZSCAN26
chr6
28267010
28278224
+
STRN3
chr14
30893799
31026401
-
ADARB1
chr21
45073853
45226560
+
KLHL28
chr14
44924319
45042322
-
WASF3
chr13
26557683
26688948
+
BTN3A1
chr6
26402237
26415208
+
CRCP
chr7
66114604
66154568
+
FCF1
chr14
74713144
74738620
+
ARMC8
chr3
138187248
138298384
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001495
chr5
68470703
68471364
+
hsa_circ_0000494
chr13
76134888
76143643
+
hsa_circ_0000018
chr1
15860731
15863309
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC015871.3
chr15
79920195
79922455
-
AC021078.1
chr5
149494314
149504670
-
AC021092.1
chr19
44103007
44113183
-
AC024940.6
chr12
31280422
31280895
-
AC084082.1
chr8
66112667
66126632
+
AC087477.2
chr15
96354237
96405235
+
AC243964.3
chr19
44631573
44725217
-
AL031428.1
chr1
23020147
23088058
-
AL137782.1
chr13
75549773
75807120
+
AL158206.1
chr9
19453209
19455173
+
AL161772.1
chr13
20699307
20703718
-
ARHGAP27P1-BPTFP1-KPNA2P3
chr17
64749663
64781707
-
CKMT2-AS1
chr5
81201341
81301565
-
EPB41L4A-AS1
chr5
112160526
112164818
+
ERICD
chr8
140636281
140638283
+
FGD5-AS1
chr3
14920347
14948424
-
H19
chr11
1995176
2001470
-
HAGLR
chr2
176164051
176188958
-
HOTAIR
chr12
53962308
53974956
-
MALAT1
chr11
65497688
65506516
+
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
SNHG16
chr17
76557764
76565348
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE101841
Sample Source:Blood
Source Fraction:Serum
Platform:GPL23138
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:1808
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.



Reference

PMID:29691399
Title:A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:Nat Commun. 2018 Apr 24;9(1):1614.
Description:MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.